Verastem, Inc. (VSTM): Price and Financial Metrics
VSTM Price/Volume Stats
| Current price | $13.45 | 52-week high | $15.18 |
| Prev. close | $13.45 | 52-week low | $4.20 |
| Day low | $13.12 | Volume | 147,400 |
| Day high | $14.09 | Avg. volume | 121,119 |
| 50-day MA | $9.42 | Dividend yield | N/A |
| 200-day MA | $8.58 | Market Cap | 340.29M |
VSTM Stock Price Chart Interactive Chart >
Verastem, Inc. (VSTM) Company Bio
Verastem, Inc. focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. The company was founded in 2010 and is based in Needham, Massachusetts.
Latest VSTM News From Around the Web
Below are the latest news stories about VERASTEM INC that investors may wish to consider to help them evaluate VSTM as an investment opportunity.
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet TherapeuticsBOSTON, December 18, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program of its discovery and development collaboration with GenFleet Therapeutics ("GenFleet"). |
3 Off-the-Beaten-Path Stocks Poised for Substantial GrowthAs horror film fans know, there’s safety in numbers but robust profitability may be more closer to the domain of uncommon stocks to buy for growth. |
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerBOSTON, December 13, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG-3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of recurrent low-grade serous ovarian cancer (LGSOC). |
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside PotentialIf the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. |
3 Penny Stocks to Buy to Turn $1 into $100: November 2023Are you looking for outsized gains for your portfolio. |
VSTM Price Returns
| 1-mo | 34.50% |
| 3-mo | 110.82% |
| 6-mo | 37.10% |
| 1-year | 64.83% |
| 3-year | -54.25% |
| 5-year | -64.42% |
| YTD | 65.23% |
| 2023 | 68.53% |
| 2022 | -80.37% |
| 2021 | -3.76% |
| 2020 | 58.96% |
| 2019 | -60.12% |
Continue Researching VSTM
Here are a few links from around the web to help you further your research on Verastem Inc's stock as an investment opportunity:Verastem Inc (VSTM) Stock Price | Nasdaq
Verastem Inc (VSTM) Stock Quote, History and News - Yahoo Finance
Verastem Inc (VSTM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...